1 Undergraduate, Department of Oral Pathology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077. Email: 152001076.sdc@saveetha.com
2 Department of Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
Received: 20th Feb, 2026 | Revised: 4th Mar, 2026 | Accepted: 25th Mar, 2026 | Available Online: 10th Apr, 2026
Introduction: Numerous studies have been conducted on liposomes as potential drug delivery methods for conditions such as lung cancer. Liposomes are lipid bilayer-based tiny vesicles that can enclose medications. This protects the medications and enhances their delivery to the target tissues. Liposomes can be utilised to encapsulate chemotherapy medications or other therapeutic agents and transport them directly to cancer cells in the lungs in the context of lung cancer. Using liposomes to treat lung cancer has a number of benefits. Here we use omega 3 fatty acids, because it is cheaper.
Materials and Methods: In this method, an ethanol phospholipid solution is injected into an agitated aqueous solution. Diffusion of ethanol in aqueous solution causes the dissolved phospholipids to precipitate and form bilayer phospholipid fragments. These fragments then fuse to form closed liposomal structures, which are then loaded with an anticancer drug.
Results: Liposomes are spherical vesicles with an aqueous core and lipid bilayer that have the ability to encapsulate medications that are both hydrophilic and hydrophobic with little to no toxicity. With a particle size ranging from 0.02-1000 μm, these vesicles enable targeted passive delivery to the deeper tissues of the tumor.
Conclusion: Finally, liposomal drug delivery systems have a lot of promise to improve treatment for lung cancer. Liposomes can increase treatment safety and efficacy through sustained drug release, improved drug accumulation, combination therapy, overcoming drug resistance, and targeted drug delivery. They can be applied in diagnostic contexts as well. Because these developments maximise drug concentration at the tumour site, reduce off-target effects, and allow for more customised treatment plans, lung cancer patients may benefit from improved outcomes. The treatment landscape for lung cancer may be greatly improved with further research and development into liposomal drug delivery systems, which could lead to improved patient outcomes and a higher standard of living.
Keywords: liposomes, lipid bilayer, small vesicles, encapsulate, omega 3 fatty acids.
How to cite this article: Afrin Nisha M, Bargavi P. Enhancing Lung Cancer Treatment via Liposome-Driven Drug Delivery Systems. Int J Drug Deliv Technol. 2026;16(29s):137-141. DOI: 10.25258/ijddt.16.29s.17
Source of support: Nil.
Conflict of interest: The authors declare no conflict of interest.